Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000905148-25-004065·Trevi Therapeutics, Inc.
Schedule 13G ownership disclosure
Trevi Therapeutics Inc
Common Stock, $0.001 par value per share · CUSIP: 89532M101
Event date: 2025-09-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- VIKING GLOBAL INVESTORS LP
Shares: 5,128,875 · Class: 4.2%
- Viking Global Opportunities Parent GP LLC
Shares: 5,128,875 · Class: 4.2%
- Viking Global Opportunities GP LLC
Shares: 3,436,346 · Class: 2.8%
- Viking Global Opportunities Portfolio GP LLC
Shares: 3,436,346 · Class: 2.8%
- Viking Global Opportunities Illiquid Investments Sub-Master LP
Shares: 3,436,346 · Class: 2.8%
- Viking Global Opportunities Drawdown GP LLC
Shares: 1,692,529 · Class: 1.4%
- Viking Global Opportunities Drawdown Portfolio GP LLC
Shares: 1,692,529 · Class: 1.4%
- Viking Global Opportunities Drawdown (Aggregator) LP
Shares: 1,692,529 · Class: 1.4%
- HALVORSEN OLE ANDREAS
Shares: 5,128,875 · Class: 4.2%
- Ott David C.
Shares: 5,128,875 · Class: 4.2%
- Shabet Rose Sharon
Shares: 5,128,875 · Class: 4.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000905148-25-004065
- Form type
- SCHEDULE 13G/A
- Filer
- Trevi Therapeutics, Inc.
- CIK
- CIK 1563880
- Filed
- Nov 14, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership